Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Published:2010-02-01 Issue:16 Volume:29 Page:2346-2356
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Ercan D,Zejnullahu K,Yonesaka K,Xiao Y,Capelletti M,Rogers A,Lifshits E,Brown A,Lee C,Christensen J G,Kwiatkowski D J,Engelman J A,Jänne P A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2009526.pdf

Reference44 articles.

1. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R et al. (2002). Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110–124.

2. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF et al. (2006). Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 12: 6494–6501.

3. Besse B, Eaton Kd, Soira JC, Lynch TJ, Miller V, Wong KK et al. (2008). Neratinib (HKI272) an irreversible pan-ErbB receptor tyrosine kinase inhibtor: preliminary results of a phase 2 tiral in patients with advanced non-small cell lung cancer. Euro J Cancer 6: 64; abstract 203..

4. Bradeen HA, Eide CA, O'Hare T, Johnson KJ, Willis SG, Lee FY et al. (2006). Comparison of imatinib mesylate, dasatinib (BMS-354825) and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood 108: 2332–2338.

5. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK et al. (2005). Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102: 11011–11016.

Cited by 202 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The evolutionary theory of cancer: challenges and potential solutions;Nature Reviews Cancer;2024-09-10

2. Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer;European Journal of Cancer;2024-09

3. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies;Cancer Communications;2024-08-19

4. Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET Inhibitors;Cancer Discovery;2024-04-02

5. Alectinib continuation beyond progression in ALK-positive non-small cell lung cancer with alectinib-refractory;Translational Lung Cancer Research;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3